![](https://www.diabetesnews.com/wp-content/uploads/2014/03/1360467286_2048_Pills-150x150.jpg)
A Novo Nordisk drug, IDegLira which combines its long-acting insulin degludec with its type 2 diabetes treatment Victoza, maintained superior blood sugar reduction after one year.
A Novo Nordisk drug, IDegLira which combines its long-acting insulin degludec with its type 2 diabetes treatment Victoza, maintained superior blood sugar reduction after one year.